논문검색
Author Jung-Hye Choi, M.D., Ph.D., Jae-Hoon Yoon, M.D. and Seong-Kyu Yang, M.D.
Place of duty Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea
Title Clinical Value of New Staging Systems for Multiple Myeloma
Publicationinfo Cancer Res Treat 2007 Dec; 039(04): 171-174.
Key_word Southwest Oncology Group staging system, International Staging System, Multiple myeloma
Full-Text
Abstract Purpose: We wanted to investigate the validity of the recently introduced Southwest Oncology Group (SWOG) staging system and the International Staging System (ISS) by comparing both systems with the widely accepted Durie/Salmon (DS) system for multiple myeloma patients. Materials and Methods: Between 1992 and 2005, 85 multiple myeloma patients (men: women 41:44, median age: 63 years (range: 36∼87)) with available baseline values of albumin and Ղ2-microglobulin were enrolled. The clinical and laboratory data were retrospectively obtained. Results: According to the ISS, 11 patients were stage I (12.9%), 30 patients stage II (35.3%) and 44 patients stage III (51.8%). The median survivals of the ISS stages I, II and III were 78.6 months, 31.8 months and 15.1 months, respectively (p=0.015). The DS staging system was not able to predict the survival. For the SWOG staging system, 14 patients were stage I (16.4%), 27 patients stage II (31.8%), 27 patients stage III (31.8%) and 17 patients were stage IV (20.0%). The median survivals of the SWOG staging system stage I, II, III and IV were 78.6 months, 31.8 months, 11.6 months and 24.8 months, respectively (p=0.0075). Conclusion: The ISS staging system showed better reliability, simplicity and predictability for survival than the DS and SWOG staging systems for multiple myeloma patients. (Cancer Res Treat. 2007;39:171-174)
출판정보 대한암학회지 2007 Dec; 039(04): 171-174.